China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
Founded in 1988, the China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA will exert great effort on “academia-industry collaboration”, which centres on the principle of “innovation, industrialization, internationalization” and persists in innovation to achieve unmet clinical requirements.
Currently, PhIRDA has 142 members, which mainly consist of five major categories: First, start-up and R&D enterprises focusing on innovation of pharmaceutical products; Second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; Third clinical institutions featuring high skills in applicable research on new drugs, especially those that undertake “major new drug innovation” technological platform for good clinical practice; Fourth, investment institutions committing to pharmaceutical innovation; Fifth, national pharmaceutical enterprises excelling at innovation; Moreover, PhIRDA has established a Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee and Pharmaceutical Innovation Investment Specialty Committee, in order to promote innovation as the goal of organizational structure.
PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
Contact
Address: Room 601, CTYS Plaza, No. 5 Dongzhimen South Street, Dongcheng District, Beijing, P.R. CHINA
Tel: +86 10-58156353
Email: luxt@phirda.com, ruanxx@phirda.com
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…
The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic,…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.…
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
See our Cookie Privacy Policy Here
